BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) | RFA MH 19 136

Frequently Asked Questions (FAQs)

What is this NIH BRAIN Initiative funding opportunity?

This opportunity is the NIH BRAIN Initiative R01 titled "Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-MH-19-136). It supports research projects that create and rigorously validate new neurotechnology tools for studying brain function at the level of specific cell types and defined neural circuits.

What is the main purpose of the program?

The main purpose is to push beyond current technical limits by developing tools that enable researchers to analyze complex brain circuitry in much greater detail. The intent is to improve understanding of cellular interactions that drive brain function by enabling precise cell-type and/or circuit-level access for labeling, monitoring, manipulation, or perturbation.

What kinds of projects does this FOA support?

The FOA supports technology development projects that produce novel tools and include a clear, rigorous validation plan demonstrating that the tool works and is genuinely useful in real experimental settings. The focus is on enabling cell-specific and circuit-specific studies rather than broad, non-specific approaches.

What does "cell-specific and circuit-specific" mean in this context?

It refers to tools designed to target particular neuronal or glial cell types and/or defined neural circuits with high precision. The expectation is that the technology enables experiments where researchers can access the right cells in the right circuit at the right time, making it easier to interpret causality in circuit function.

Are incremental improvements to existing tools competitive?

The FOA expresses strong interest in tools that provide major capability jumps, meaning approaches that break through existing barriers rather than offering only small incremental improvements.

Is validation required, or can it be a secondary aim?

Validation is an essential feature of a competitive application, not a side aim. Applicants are expected to include a clear plan to demonstrate that the tool works and is useful.

What types of validation does NIH expect?

Validation would typically include demonstrating performance characteristics such as specificity (targeting the intended cell type or circuit), sensitivity (detecting or affecting targets reliably), precision (spatial and temporal control), reproducibility, and practical utility in real experimental settings.

Does this FOA limit the types of tools that can be proposed?

The announcement does not restrict applicants to a short list of tool types. The scope is consistent with novel delivery vectors, engineered molecular systems, targeting strategies, and other enabling technologies designed for cell- and circuit-specific access in the nervous system.

Are both genetic and non-genetic approaches allowed?

Yes. The FOA explicitly encourages both genetic and non-genetic strategies for delivering genes, proteins, or chemicals to cells of interest, as well as other approaches that can target specific neuronal or glial populations or defined circuits with higher precision and sensitivity than standard techniques.

What does the FOA mean by "broadly usable tools"?

Broadly usable tools are technologies designed for adoption beyond the original development lab. The FOA indicates that tools usable across multiple species or model organisms are especially valuable compared with tools that only work in a single species.

Is cross-species applicability important?

Yes. The announcement states that technologies that can be applied across multiple species or model organisms are viewed as especially valuable, supporting the BRAIN Initiative goal of producing widely adoptable resources that accelerate progress across many areas of neuroscience.

What grant mechanism is used for this opportunity?

This opportunity uses the NIH R01 grant mechanism, which is intended for substantial projects with a well-developed research plan and meaningful scope of work.

Are clinical trials allowed under this FOA?

No. The listing specifies "Clinical Trial Not Allowed," so applications proposing clinical trials are not eligible under this announcement. The focus is tool development and validation rather than testing interventions in clinical trial frameworks.

What is the funding instrument type?

The funding instrument type is a grant.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities categorized as "others."

Are foreign (non-U.S.) organizations eligible?

Yes. The announcement includes foreign (non-U.S.) organizations among eligible applicants.

Are federally recognized tribal governments and other tribal entities eligible?

Yes. The eligibility list includes federally recognized Native American tribal governments and also tribal organizations that are not federally recognized.

Are minority-serving institutions and other specific institution types encouraged or eligible?

Yes. The announcement highlights additional eligible applicant groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and also faith-based or community-based organizations.

Are federal agencies eligible to apply?

Yes. The announcement notes eligible federal agencies among the additional eligible applicant groups.

Are U.S. territories or possessions eligible?

Yes. The announcement includes U.S. territories or possessions among eligible applicant groups.

What kinds of applicants beyond universities might be a fit?

Based on the eligibility list, potential applicants can include government entities, nonprofits (with or without 501(c)(3) status, other than institutions of higher education), for-profit organizations (other than small businesses), small businesses, independent school districts, public housing authorities/Indian housing authorities, and regional organizations, among others.

What makes a strong application under this FOA?

A strong application would typically (1) make a compelling case that the proposed tool fills a real gap in current neuroscience capabilities, (2) explain why existing methods are insufficient, (3) show a realistic development path with clear benchmarks and validation experiments, (4) describe how the tool achieves cell-type and/or circuit specificity, (5) explain how performance will be measured, and (6) address how the technology could be adopted by the broader community, ideally across multiple model systems.

What is the overarching goal of funding tool development here?

The goal is not tool building for its own sake. The goal is to build tools that enable new kinds of cell- and circuit-specific experiments that were previously difficult or impossible, accelerating the pace and depth of discovery about how the brain functions.

What NIH activity areas and CFDA numbers are associated with this opportunity?

The opportunity is categorized within NIH activity areas spanning education, health, income security, and social services in the federal listing, with multiple CFDA numbers associated with NIH programs: 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.313, 93.853, 93.865, 93.866, 93.867.

Does the FOA emphasize targeting specificity over broad approaches?

Yes. Projects are expected to produce tools that take advantage of, or directly enable, precise cell-type and/or circuit-level targeting rather than broad, non-specific approaches.

What kinds of scientific use cases does the FOA seem designed to enable?

The described emphasis is on enabling experiments that dissect causality in brain circuits by improving the ability to label, monitor, manipulate, or perturb specific cells within defined circuits with confidence in the interpretation.